Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904864 | 0.78 | — | — | |
| SCHEMBL2198261 | 0.78 | HSD11B1 (0.31) | — | |
| SCHEMBL21646570 | 0.78 | — | — | |
| SCHEMBL25316524 | 0.76 | — | — | |
| SCHEMBL1204756 | 0.75 | CA1 (0.32) | CA2 | |
| SCHEMBL22802911 | 0.74 | — | — | |
| SCHEMBL21719642 | 0.73 | — | — | |
| SCHEMBL12221323 | 0.73 | — | — | |
| SCHEMBL12221381 | 0.73 | — | — | |
| SCHEMBL31503587 | 0.73 | ALDH1A1 (0.39) | LMNAALDH1A1CA2POLBTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4262718-A1 | DYEING COMPOSITION BASED ON 2-GAMMA-HYDROXYPROPYL-PARA-PHENYLENEDIAMINE AND A PHOSPHORIC SURFACTANT | L'OREAL (FR) | 2023-10-25 | — | — | EP | disclosed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-8153664-B2 | thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer | SCHERING CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110038835-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2011010222-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2011-01-27 | — | — | WO | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | MERCK SHARP & DOHME CORP. | 2009-08-06 | — | — | US | disclosed |
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-10-30 | — | — | US | disclosed |
| US-20080090830-A1 | Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090830-A1 | Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists | EDNRB, TBXA2R, BDKRB1 | KCNH2 1411/4885LMNA 874/4885APEX1 3264/4885 |
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | KCNH2 2301/4885LMNA 1504/4885APEX1 3124/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | KCNH2 3800/4885LMNA 106/4885APEX1 2993/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | KCNH2 4069/4885LMNA 2503/4885APEX1 2137/4885 |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM1, GRM4, GRM3 | KCNH2 1226/4885LMNA 4660/4885APEX1 3735/4885 |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | LTC4S, LTA4H, ALOX5 | KCNH2 3875/4885LMNA 1312/4885APEX1 657/4885 |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ABL1, MCL1, ABL2 | KCNH2 4057/4885LMNA 2691/4885APEX1 3957/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | KCNH2 4815/4885LMNA 3802/4885APEX1 265/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | KCNH2 4834/4885LMNA 2516/4885APEX1 1234/4885 |
| US-20110038835-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, RHOA, ROCK2 | KCNH2 4508/4885LMNA 3205/4885APEX1 1895/4885 |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | TRIM33, TRIM28, TRIM4 | KCNH2 4802/4885LMNA 1670/4885APEX1 1198/4885 |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | ALOX5, LTC4S, ALOX15B | KCNH2 2371/4885LMNA 1243/4885APEX1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.